EMMANUEL BARRON: Open Payments
NPI 1598398034 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,071 in 122 payments from 14 companies in 2025. Trend: 2023 $1,354 · 2024 $2,352 · 2025 $3,071
Food & beverage: $3,071
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 54 | $1,445 |
| Gilead Sciences, Inc. | 25 | $592 |
| Theratechnologies Inc. | 7 | $200 |
| Otsuka America Pharmaceutical, Inc. | 6 | $161 |
| Novo Nordisk Inc | 8 | $156 |
| Novartis Pharmaceuticals Corporation | 6 | $135 |
| Merck Sharp & Dohme LLC | 4 | $117 |
| Lilly USA, LLC | 3 | $58 |
| Corcept Therapeutics | 2 | $57 |
| ABBVIE INC. | 2 | $42 |
Products named: APRETUDE, DOVATO, CABENUVA, EGRIFTA, REXULTI, LEQVIO, PIFELTRO, Wegovy.
Industry payments across IL — which companies pay providers there.
